OPINION Testosterone and weight loss: the evidence
INTRODUCTION
Obesity impacts quality of life and shortens life expectancy. Obesity is a chronic condition that cannot be ameliorated simply with lifestyle behavior alone [1, 2] . Obesity contributes to insulin resistance, type 2 diabetes (T2DM) and is associated with a host of comorbidities and therefore represents a healthcare crisis. Lifestyle changes produce modest weight loss in the early stages of weight management strategies, but a high rate of recidivism is observed. Treatment of obesity necessitates evidence-based medical interventions [3, 4] . Although lifestyle modifications are highly recommended, as integral part of strategies designed for treatment and management of obesity [5] [6] [7] , in most patients, such strategies are not always successful in the long term because of high rate of recidivism, in part due to lack of adherence to prescribed regimen [8] [9] [10] [11] . The limited benefits of the current approved drugs, together with the undesirable adverse side-effects of such agents in long-term management of obesity have contributed to reduced adherence rates and to discontinuation of use [2] . Efforts to target patient education and increase awareness are warranted.
Desirable outcomes in management of overweight and obesity necessitates development and utilization of new well tolerated and efficacious agents, which can be used in combination with lifestyle changes to achieve weight loss. Contemporary approaches to management of obesity include lifestyle modifications [12] and pharmaco-therapeutic agents, such as incretin and glucagon-like
NEW APPROACHES FOR TREATMENT OF OBESITY IN MEN WITH TESTOSTERONE DEFICIENCY (HYPOGONADISM)
The prevalence of testosterone deficiency increases with comorbidities, such as insulin resistance and T2DM, obesity, hypertension, and cardiovascular disease (CVD) ranging from 30 to 50% [18] [19] [20] [21] . Mulligan et al. [18] reported that approximately 52.4% of all obese men had testosterone levels below 300 ng/dl (10.4 nmol/l). Similarly, Luconi et al. [22] suggested that approximately 75% of men with obesity grade III awaiting bariatric surgery had hypogonadism. In our study of 255 hypogonadal men, we noted 71% of men were obese and 14.1% had obesity grade III, using a testosterone cut-off of 12.1 nmol/l [23 && ]. Testosterone levels are reduced with increased waist circumference and obesity [17, 24] and approximately 40% of obese nondiabetic men and 50% of obese diabetic men aged above 45 years have low free testosterone [18, 25] . The concomitant presence of obesity and diabetes is associated with an additional increase in prevalence of testosterone deficiency approaching 34% [18, 19, 25, 26] .
Testosterone therapy in men with testosterone deficiency (hypogonadism) has profound effects on body composition, resulting in reduced fat mass, increased lean body mass (LBM) ( Table 2 ). The effects of testosterone therapy on increased LBM and reduced fat mass and the changes in anthropometric parameters were consistently reported in most studies [20] [21] [22] 23 (Tables 1 and 2 ), Allan and Mclachlan [68] proposed the use of testosterone therapy in men with testosterone deficiency for management of obesity. Saad et al. [69] further proposed testosterone therapy as a new potential intervention strategy for managing obesity in hypogonadal men (testosterone deficiency). The data from recent studies with longterm testosterone therapy in men with testosterone deficiency, using testosterone formulations which result in sufficient circulating physiological testosterone levels and good patient adherence, reported significant and sustained weight loss, reduced BMI potential mechanisms involved in low testosterone levels in obesity encompass complex mechanisms, including increased levels of sex hormone binding globulin (SHBG), low or inappropriate normal levels of luteinizing hormone, adipocyte dysfunction, androgen resistance and insulin resistance. Loss of androgen receptor function increases the number of adipocytes and the accumulation of visceral fat [80] . Low baseline testosterone predicts obesity in men [81] and normalization of physiological testosterone levels reduces the activity of lipoprotein lipase and tryglycerides [77] . Testosterone treatment results in improved insulin sensitivity, lipid oxidation and reduction in fat mass with concomitant gain in fat free mass. Camacho et al. [78 & ] reported that weight loss is associated with increased testosterone levels, a finding supported by Corona et al. [79] . Intervention measures, such as diet and exercise or surgical treatment of obesity, results in increased testosterone levels [79, 82, 83] .
KEY POINTS

Effects of testosterone therapy on myogenesis and adipogenesis
Androgens regulate myogenesis and inhibit adipogenesis [67, [84] [85] [86] [87] [88] . Maneschi et al. [89] reported that testosterone therapy preserves visceral adipose tissue function, and testosterone deficiency results in derangement and dysfunction of visceral adipose tissue metabolism. Men with testosterone deficiency and obesity have reduced testosterone levels and weight loss produces increased total testosterone levels [79,78 & ].
Effects of testosterone therapy on carbohydrate, protein and fat metabolism
Testosterone regulates carbohydrates, proteins and fat metabolism [79, 89] and testosterone therapy in men with testosterone deficiency results in normalization of glucose utilization and increased lipid oxidation [90] . Testosterone deficiency affects energy production and utilization and therefore upsets this physiological balance resulting in storage of lipids and increased adipogenesis and altering mitochondrial function [89] [90] [91] [92] [93] [94] . Obesity contributes to premature cardiac aging via disrupted mitochondrial biogenesis and function and is an independent risk factor for development of heart failure [92] [93] [94] . Testosterone therapy ameliorates this dysfunction.
Effects of testosterone therapy in men with testosterone deficiency on fatigue, motivation, vigor and physical activity Yu and Traish [95] suggested that testosterone deficiency contributes to fatigue via alterations of mitochondrial function and energy production and [96] . The increased motivation, energy and reduced fatigue in response to testosterone therapy significantly contribute to more physical activity, thus resulting in increased energy utilization associated with increased muscle mass and improved mitochondrial function. This, in part, explains the observed weight loss with testosterone therapy in men treated for long durations with appropriate testosterone formulations producing physiological levels [58 && -61 && ,72]. In contrast, androgen deprivation therapy (ADT) used in management of hormone-dependent prostate cancer results in fatigue and reduces energy and motivation [95, 97] .
Effects of testosterone therapy on fat deposition and vascular health
Weight gain is attributed to 88% increased fat mass, and weight loss is associated with 72% decrease in fat mass and 28% decrease in LBM [98] . One of the key observations in testosterone therapy is that testosterone increases LBM, thus increasing resting energy expenditure. Testosterone therapy in men with testosterone deficiency with or without diet and physical activity not only produced reduction in fat mass but also improvements in cardiometabolic function and reduced carotid intima media thickness (CIMT), epicardial fat and trunk fat [46 && ,58 && ,70]. Also reduction in CIMT was noted with testosterone but not with diet and physical exercise alone. Reduction in CIMT with testosterone therapy was previously demonstrated [42, 71] . Testosterone therapy for 18 weeks reduced ectopic and liver fat in obese men [99 & ], suggesting that testosterone therapy has a protective effect on the 
CHALLENGES AND LIMITATIONS OF TESTOSTERONE THERAPY IN OBESE MEN WITH TESTOSTERONE DEFICIENCY
Among the challenges of testosterone therapy is the myth that testosterone causes prostate cancer (PCa). Although this myth has been debunked [108, 109] , the fear of physicians from litigation has presented a ].
Obesity and nutrition huge challenge to testosterone therapy in men with testosterone deficiency [110, 111] . Recently, another challenge was raised suggesting that testosterone therapy causes myocardial infarctions (MIs), stroke and death [112] [113] [114] . Although these reports suffer from serious methodological flaws and poor scientific evidence-based medicine, the purported information that testosterone therapy is harmful has confounded the knowledge gained from more than 4 decades of experience with testosterone therapy, and is in direct contradiction with this large body of actual patient data [115] . A large number of studies have shown that testosterone therapy does not increase the risk of MI, stroke or death [115] . On the contrary, testosterone deficiency is considered a risk of CVD [115] . Jespersen et al. [116] reported ADT is associated with greater risk for MI and stroke in men with PCa. Keating et al. [117] showed that ADT is associated with worsening of diabetes control and increased despite the use of other diabetes medications.
EXPERT OPINION
One may argue that testosterone therapy has been around for more than 75 years and no data have been reported on the effects of testosterone on weight loss, until recently. So, why now and how could this be explained? Several key reasons explain this deficit in the literature. First, most studies reported on testosterone therapy were of very short duration and this does not permit necessary tissue remodeling and changes in LBM and fat mass, which require longer time periods. Second, testosterone formulations used in many prior studies did not provide sustained physiological levels of testosterone and in most cases the circulating testosterone levels were suboptimal, thus resulting in incomplete responses. Third, in addition, poor patients' compliance to testosterone therapy is of paramount importance in the effectiveness of testosterone therapy. These factors explain, in part, the neutral effects of testosterone therapy on weight observed in some studies. Schoenfeld et al. [118] showed that adherence rates to testosterone therapy are variable depending on formulations and therefore differing outcomes are expected. It should be noted that testosterone deficiency is associated with a shift in fuel metabolism from lipid oxidation toward glucose utilization [119] and testosterone therapy [51, 120] increased muscle mass and lipid oxidation in aging men. Furthermore, higher endogenous circulating testosterone levels were associated with reduced loss of LBM in elderly men [121] and testosterone therapy in frail men preserves muscle thickness [122] . Thus, it is not surprising that in obese men with testosterone deficiency, long-term testosterone therapy with formulations that achieve physiological levels, along with adequate adherence, produced significant and sustained weight loss, concomitant with reduction in waist circumference and BMI ( [104] [105] [106] [107] 123] . We suggest that testosterone therapy offers well tolerated and effective treatment of obesity in men with testosterone deficiency and this novel approach provides a unique opportunity to manage obese men. Other therapeutic targets for the treatment of obesity have been proposed including hypothalamic malonyl-CoA and CPT1c [124, 125] and GLP-1, oxyntomodulin, peptide YY, gastric inhibitory peptide and ghrelin [126] . These targets may prove useful in addition to testosterone therapy.
CONCLUSION
Lifestyle modifications are considered a cornerstone in combating obesity. However, this is difficult to maintain over the long term, and the ability to achieve modest weight loss with lifestyle modification is limited, at best. Pharmacotherapy coupled with lifestyle modification provides an alternative to combating obesity with lifestyle changes alone. We propose that testosterone therapy in obese men with testosterone deficiency offers a well tolerated and effective therapy and produces sustained and significant weight loss. Testosterone therapy increases LBM, reduces fat mass and produces sustained and significant weight loss, reduction in waist circumference and BMI. We believe that testosterone therapy in obese men with testosterone deficiency is a unique and effective therapeutic approach to management of obesity. The fact that this therapy has been used over the past 7 decades to treat hypogonadism (testosterone deficiency) and is proven to be well tolerated and effective should be an added tool to the armament for the war on obesity. This study experimentally showed that mid-normal levels of testosterone are required to prevent an increase in fat mass.
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